The global acute radiation syndrome market size is estimated to be valued at USD 5.47 Billion in 2025. It can reach a valuation of USD 7.80 Billion by 2032, exhibiting a CAGR of 5.2% throughout the forecast period (2025-2032).  

The increasing awareness and preparedness levels for nuclear incidents is expected to drive the market growth. Government initiatives for the development of therapeutics and their stockpiling for a proper defense against acute radiation syndrome (ARS) can facilitate the market growth.

However, the high costs associated with the development of radiation countermeasures can impede the market growth.

Key Market Insights

The acute radiation syndrome market is predicted to be shaped by the integration of artificial intelligence (AI) in treatment protocols and the expansion of nuclear power projects.

• By radiation type, the non-ionizing radiation segment is expected to capture a 31.8% share of the market in 2025. The need for comprehensive safety measures as part of nuclear incident preparedness can drive the segment’s growth over the forecast period.
• By product type, the tablets segment is anticipated to retain 20% market share in 2025. Tablets can account for a significant market share owing to their stability in long-term storage and their ease in stockpiling.
• By region, the Asia Pacific region is projected to grow at a rapid pace in 2025. The investments in nuclear emergency response infrastructure to strengthen their ARS countermeasures can drive the regional market growth.

The full report is now available for purchase: https://www.coherentmi.com/industry-reports/acute-radiation-syndrome-market

Acute Radiation Syndrome Market Report Coverage

Market Dynamics

The risks of nuclear contamination outside production sites can drive the acute radiation syndrome market growth. Stockpiling initiatives and geopolitical instability among nations can also drive the market growth significantly. This can be exemplified by the collaboration agreement signed between the government of Ukraine and Pluri, an Israel-based developer of placenta-based cell technology, on March 05, 2025. The placental expanded cell therapy developed by the latter and its distribution in the event of life-threatening radiation sickness can bolster the market growth.

The expansion of nuclear power plants by countries worldwide is anticipated to open up new avenues for the market. The International Atomic Energy Agency (IAEA) has supported 12 countries in this regard and proposed activities throughout 2025 to enhance collaboration.

Market Opportunity: Collaboration with Pharmaceutical Companies

Pharmaceutical companies are signing pacts with governments with nuclear facilities to provide ARS medications in case of emergencies. The demand for the development of effective treatments against hematopoietic, gastrointestinal, and neurovascular syndromes of ARS can augur favorably for the acute radiation syndrome market.

Market Challenge: Limited Demand Outside Emergency Scenarios

The infrequency of ARS outside radiological incidents or nuclear accidents can limit the market growth severely. Additionally, the lack of a robust supply chain for the deployment of treatments to all regions can be detrimental to the market growth.

Analyst’s View

• The prioritization of nuclear safety by governments can drive the acute radiation syndrome market growth.
• The non-ionizing radiation segment is expected to account for a significant market share in 2025, owing to the demand for radiation safety protocols.
• Key players are partnering with contract firms to maintain their production capacity.

Recent Developments

Partner Therapeutics, Inc. (PTx) gained marketing authority approval for IMREPLYS for the treatment of acute radiation syndrome for patients of all ages on June 20, 2025.

Competitor Insights

• Mission Pharmacal Company
• Cellerant Therapeutics
• Novartis AG
• Amgen
• Recipharm AB
• NeoImmuneTech
• Partner Therapeutics
• Mylan NV
• Pluristem Therapeutics
• Partner Therapeutics
• Humanetics Corporation
• Statera BioPharma

Market Segmentation

• By Radiation Type
• Ionizing Radiation
• Non-ionizing Radiation
• By Product Type
• Capsules
• Tablets
• Parenterals
• Others

Regional Insights

• North America
  • U.S.
  • Canada
• Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
• Europe
  • Italy
  • Germany
  • U.K.
  • Spain
  • Russia
  • France
  • Rest of Europe
• Asia Pacific
  • South Korea
  • India
  • China
  • Japan
  • Australia
  • ASEAN
  • Rest of Asia Pacific
• Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
• Africa
  • South Africa
  • North Africa
  • Central Africa